Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

REGN

Regeneron Pharmaceuticals, Inc

Dec 20 • 04:00PM ET

701.85

Dollar change -6.40
Percentage change -0.90	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD VRTX MRNA BMRN INCY EXEL IONS

| Held by: VTI VOO QQQ SPY IVV VTV XLV JEPI IBB VHT

Scroll to Statements

Index	NDX, S&P 500	P/E	17.37	EPS (ttm)	40.41	Insider Own	3.61%	Shs Outstand	108.30M	Perf Week	-4.03%
Market Cap	76.43B	Forward P/E	15.69	EPS next Y	44.75	Insider Trans	-0.97%	Shs Float	105.92M	Perf Month	-5.58%
Income	4.65B	PEG	2.67	EPS next Q	11.30	Inst Own	85.68%	Short Float	1.70%	Perf Quarter	-35.73%
Sales	13.85B	P/S	5.52	EPS this Y	2.79%	Inst Trans	-1.13%	Short Ratio	2.15	Perf Half Y	-34.03%
Book/sh	266.36	P/B	2.63	EPS next Y	-0.59%	ROA	13.37%	Short Interest	1.80M	Perf Year	-16.62%
Cash/sh	89.96	P/C	7.80	EPS next 5Y	6.50%	ROE	17.17%	52W Range	693.00 - 1211.20	Perf YTD	-20.09%
Dividend Est.	-	P/FCF	22.22	EPS past 5Y	10.31%	ROI	14.53%	52W High	-42.05%	Beta	0.10
Dividend TTM	-	Quick Ratio	4.46	Sales past 5Y	19.99%	Gross Margin	82.74%	52W Low	1.28%	ATR (14)	21.14
Dividend Ex-Date	-	Current Ratio	5.28	EPS Y/Y TTM	15.72%	Oper. Margin	29.89%	RSI (14)	27.80	Volatility	3.14% 2.65%
Employees	13450	Debt/Eq	0.09	Sales Y/Y TTM	5.72%	Profit Margin	33.61%	Recom	1.71	Target Price	1074.73
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	29.82%	Payout	0.00%	Rel Volume	2.26	Prev Close	708.25
Sales Surprise	1.25%	EPS Surprise	6.54%	Sales Q/Q	10.65%	Earnings	Oct 31 BMO	Avg Volume	835.30K	Price	701.85
SMA20	-6.16%	SMA50	-15.05%	SMA200	-28.46%	Trades		Volume	1,887,145	Change	-0.90%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform	$1175 → $1077
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$950
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy	$720 → $992
Aug-21-23	Reiterated	Oppenheimer	Perform	$950 → $1050
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold	$953 → $720
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform	$834 → $976
Mar-24-23	Upgrade	Jefferies	Hold → Buy	$675 → $925
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform	$775 → $875
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight	$850
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line	$760
Sep-09-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$625 → $851
Sep-09-22	Upgrade	Jefferies	Underperform → Hold	$536 → $675

Show Previous Ratings

Dec-19-24 07:23AM	Regeneron says study data support big bet on new blood thinners (BioPharma Dive)
07:00AM	Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results (GlobeNewswire)
Dec-18-24 09:39PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
Dec-17-24 04:05PM	Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:34AM	Bayers Eye Drug Shows Positive Results in Late-Stage Trial (The Wall Street Journal)
07:00AM	Loading…
07:00AM	EYLEA HD (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion (GlobeNewswire)
06:53AM	Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-16-24 04:30PM	Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year (GlobeNewswire)
Dec-13-24 07:19AM	Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge (Pharmaceutical Technology)
Dec-12-24 02:26AM	Regenerons R&D approach scores dual wins against Alexions Ultomiris and in lymphoma (Pharma Voice)
Dec-11-24 01:19PM	Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900 (Insider Monkey)
07:05AM	Regeneron reinstated with an Underperform at BofA (TipRanks)
Dec-10-24 03:06PM	ASH 2024: Regenerons Ordspono faces challenges, but positive results signal hope (Pharmaceutical Technology)
12:04PM	Regeneron Pharmaceuticals (REGN): Sales Struggles and Future Prospects (Insider Monkey)
Dec-09-24 05:45PM	Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma (GlobeNewswire)
07:00PM	Loading…
Dec-07-24 07:00PM	Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab (GlobeNewswire)
Dec-02-24 07:48AM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
Nov-29-24 11:36AM	Galderma Bets on Skin Drug to Turn Around Pharma Business (The Wall Street Journal)
Nov-25-24 04:16PM	BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug (Investor's Business Daily)
08:34AM	Do Options Traders Know Something About Regeneron (REGN) Stock We Don't? (Zacks)
Nov-23-24 10:50AM	Regeneron Pharmaceuticals, Inc. (REGN): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-19-24 06:51PM	Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now (Insider Monkey)
10:16AM	Heres Why Regeneron Pharmaceuticals (REGN) Declined in Q3 (Insider Monkey)
Nov-18-24 12:45AM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
Nov-15-24 12:40PM	FDA reviews Sanofi and Regenerons Dupixent label expansion for urticaria (Pharmaceutical Technology)
01:00AM	Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria (GlobeNewswire)
12:59AM	Dupixent (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) (GlobeNewswire)
Nov-14-24 09:54AM	Citi initiates coverage on 5 new biotech stocks (Investing.com)
07:00AM	2 Top Growth Stocks to Buy on the Dip (Motley Fool)
Nov-13-24 11:06AM	Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease (Benzinga)
07:00AM	Loading…
07:00AM	Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH (GlobeNewswire)
Nov-11-24 04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
Nov-08-24 09:37AM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
Nov-07-24 06:35AM	Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer (TipRanks)
04:28AM	EMA approves Sanofi/Regenerons Dupixent for young EoE patients (Pharmaceutical Technology)
Nov-06-24 04:11AM	Is It Time to Buy October's Worst-Performing Nasdaq Stocks? (Motley Fool)
01:00AM	Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis (GlobeNewswire)
01:00AM	Dupixent (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis (GlobeNewswire)
Nov-02-24 10:35AM	Regeneron price target lowered to $1,126 from $1,137 at Truist (TipRanks)
Nov-01-24 09:08AM	What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity? (Insider Monkey)
03:05AM	Regeneron Pharmaceuticals Inc (REGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
02:55AM	Q3 2024 Regeneron Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
01:09AM	Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight (GuruFocus.com)
Oct-31-24 05:22PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research) -9.17%
04:11PM	Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom (Investor's Business Daily)
01:46PM	Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? (Benzinga)
09:30AM	Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:45AM	Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates (Zacks)
07:28AM	Regeneron shares drop as higher-dose Eylea drug misses sales estimates (Reuters)
06:52AM	Regeneron Earnings Top Views For Biotech Giant (Investor's Business Daily)
06:39AM	Regeneron: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Regeneron Reports Third Quarter 2024 Financial and Operating Results (GlobeNewswire)
Oct-28-24 12:16PM	EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss (Benzinga)
09:16AM	Unlocking Q3 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics (Zacks)
04:20AM	Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split (Motley Fool)
Oct-25-24 04:24PM	Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat (Investor's Business Daily)
01:57PM	Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent (Benzinga)
Oct-24-24 10:01AM	Regeneron (REGN) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI (GlobeNewswire)
08:00AM	Dupixent (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI (GlobeNewswire)
Oct-23-24 06:20AM	Amgen plans launch of Eylea biosimilar after court ruling (BioPharma Dive)
Oct-22-24 03:31PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
Oct-19-24 05:10PM	Regeneron announces three-year data for EYLEA HD Injection 8 mg study (TipRanks)
Oct-18-24 05:05PM	Three-year Results for EYLEA HD (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema (GlobeNewswire)
Oct-17-24 07:40AM	Regeneron price target lowered to $1,137 from $1,200 at Truist (TipRanks)
Oct-16-24 09:25AM	Is Regeneron Pharmaceuticals, Inc. (REGN) the Best High Growth NASDAQ Stock That is Profitable in 2024? (Insider Monkey)
Oct-10-24 09:35AM	Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-06-24 04:53PM	Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Morgan Stanley Overweight & Quality Stock? (Insider Monkey)
Oct-05-24 08:43AM	Regeneron Pharmaceuticals, Inc. (REGN): A Buzzing AI Health Stock to Add to Your Portfolio (Insider Monkey)
06:30AM	Should You Buy the Dip on This Top Growth Stock? (Motley Fool)
Sep-28-24 07:05AM	Regeneron, Sanofi announce Dupixent approval in China for patients with COPD (TipRanks)
06:33AM	Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling (Insider Monkey)
Sep-27-24 04:51PM	Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD (Investopedia)
04:39PM	Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling (Bloomberg)
02:53PM	FDA greenlights Regenerons Dupixent for the treatment of COPD (Pharmaceutical Technology)
12:13PM	Sanofi/Regenerons Dupixent set to dominate COPD biologics market following FDA approval (Pharmaceutical Technology)
10:24AM	Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD (The Wall Street Journal)
09:36AM	Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent (Investor's Business Daily)
09:35AM	Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD (GlobeNewswire)
09:35AM	Dupixent (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD (GlobeNewswire)
07:00AM	Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD (GlobeNewswire)
07:00AM	Dupixent (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) (GlobeNewswire)
05:35AM	FDA, after delay, clears Regeneron and Sanofi drug for COPD (BioPharma Dive)
Sep-26-24 04:05PM	Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024 (GlobeNewswire)
Sep-25-24 12:54PM	Amgen Stock Falls on Disappointing Drug Data (The Wall Street Journal)
Sep-24-24 05:13PM	S&P 500 Gains and Losses Today: Economic Stimulus Boosts China-Facing Stocks (Investopedia)
01:33PM	Top Stock Movers Now: Nvidia, Freeport-McMoRan, Visa, and More (Investopedia)
12:19PM	Regeneron slump continues as analysts turn more cautious (Investing.com)
09:15AM	Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase (PR Newswire)
Sep-23-24 07:02PM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
05:30PM	S&P 500 Gains and Losses Today: Tesla Stock Jumps as Analysts Highlight Catalysts (Investopedia)
04:34PM	Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling (Investor's Business Daily)
04:13PM	Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea (Investor's Business Daily)
Sep-20-24 07:45AM	Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old (GlobeNewswire)
07:45AM	Dupixent (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old (GlobeNewswire)
Sep-19-24 05:07PM	The best biotech plays outside the GLP-1 weight-loss market (Yahoo Finance Video)
Sep-17-24 05:22PM	Jim Cramer Says Regeneron Pharmaceuticals Inc. (REGN)s Oncology Portfolio is Beautiful (Insider Monkey)
Sep-16-24 06:33AM	ESMO 2024: Regenerons melanoma combo therapy benefit continues beyond two years (Clinical Trials Arena)
04:52AM	Regenerons Dupixent approved as first adolescent CRSwNP treatment (Pharmaceutical Technology)
Sep-13-24 12:15PM	Dupixent (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (GlobeNewswire)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McCourt Marion	EVP Commercial	Nov 01 '24	Option Exercise	381.40	1,000	381,400	13,931	Nov 05 04:23 PM
McCourt Marion	EVP Commercial	Nov 01 '24	Sale	844.61	1,000	844,610	12,931	Nov 05 04:23 PM
MARION E MCCOURT	Officer	Nov 01 '24	Proposed Sale	844.61	1,000	844,610		Nov 01 04:38 PM
RYAN ARTHUR F	Director	Oct 01 '24	Sale	1048.78	100	104,878	17,582	Oct 03 04:02 PM
McCourt Marion	EVP Commercial	Oct 01 '24	Option Exercise	381.40	1,000	381,400	13,931	Oct 03 04:02 PM
McCourt Marion	EVP Commercial	Oct 01 '24	Sale	1054.06	1,000	1,054,060	12,931	Oct 03 04:02 PM
MARION E MCCOURT	Officer	Oct 01 '24	Proposed Sale	1054.06	1,000	1,054,060		Oct 01 04:13 PM
McCourt Marion	EVP Commercial	Sep 03 '24	Option Exercise	381.40	1,000	381,400	13,931	Sep 05 04:01 PM
McCourt Marion	EVP Commercial	Sep 03 '24	Sale	1178.73	1,000	1,178,730	12,931	Sep 05 04:01 PM
RYAN ARTHUR F	Director	Sep 03 '24	Sale	1178.68	100	117,868	17,682	Sep 05 04:01 PM
MARION E MCCOURT	Officer	Sep 03 '24	Proposed Sale	1178.73	1,000	1,178,730		Sep 03 04:04 PM
Fenimore Christopher R.	SVP Finance & CFO	Aug 28 '24	Sale	1205.33	5,680	6,846,262	0	Aug 29 04:27 PM
Christopher Fenimore	Officer	Aug 28 '24	Proposed Sale	1205.21	5,680	6,845,565		Aug 28 04:35 PM
Bassler Bonnie L	Director	Aug 15 '24	Option Exercise	371.40	756	280,778	2,138	Aug 19 04:02 PM
Bassler Bonnie L	Director	Aug 15 '24	Sale	1170.00	756	884,520	1,382	Aug 19 04:02 PM
POON CHRISTINE A	Director	Aug 15 '24	Option Exercise	413.33	10,838	4,479,671	13,010	Aug 19 04:01 PM
POON CHRISTINE A	Director	Aug 15 '24	Sale	1158.17	10,838	12,552,284	2,172	Aug 19 04:01 PM
Christine Poon	Director	Aug 15 '24	Proposed Sale	1156.86	10,838	12,538,049		Aug 15 05:55 PM
MURPHY ANDREW J	EVP Research	Aug 13 '24	Option Exercise	399.66	20,000	7,993,200	68,306	Aug 15 04:01 PM
MURPHY ANDREW J	EVP Research	Aug 14 '24	Sale	1153.15	6,363	7,337,505	48,306	Aug 15 04:01 PM
Bassler Bonnie L	Director	Aug 15 '24	Proposed Sale	1170.00	756	884,520		Aug 15 11:45 AM
MURPHY ANDREW J	Officer	Aug 14 '24	Proposed Sale	1152.27	6,363	7,331,894		Aug 14 04:08 PM
STAHL NEIL	EVP Research and Development	Aug 08 '24	Sale	1084.54	5,197	5,636,346	50,999	Aug 12 04:05 PM
Neil Stahl	Officer	Aug 08 '24	Proposed Sale	1084.46	5,197	5,635,926		Aug 08 04:53 PM
Pitofsky Jason	VP Controller	Aug 07 '24	Option Exercise	372.46	487	181,388	4,691	Aug 07 04:40 PM
Pitofsky Jason	VP Controller	Aug 07 '24	Sale	1070.00	487	521,090	4,204	Aug 07 04:40 PM
Jason Pitofsky	Officer	Aug 07 '24	Proposed Sale	1069.75	487	520,970		Aug 07 04:33 PM
STAHL NEIL	EVP Research and Development	Aug 02 '24	Option Exercise	555.67	23,638	13,134,927	74,637	Aug 06 04:03 PM
Bassler Bonnie L	Director	Aug 02 '24	Option Exercise	371.40	756	280,778	2,138	Aug 05 04:05 PM
Bassler Bonnie L	Director	Aug 02 '24	Sale	1115.00	756	842,940	1,382	Aug 05 04:05 PM
McCourt Marion	EVP Commercial	Aug 01 '24	Option Exercise	372.46	1,137	423,487	14,068	Aug 05 04:04 PM
McCourt Marion	EVP Commercial	Aug 01 '24	Sale	1060.86	1,137	1,206,198	12,931	Aug 05 04:04 PM
RYAN ARTHUR F	Director	Aug 01 '24	Sale	1100.03	1	1,100	17,782	Aug 05 04:01 PM
RYAN ARTHUR F	Director	Aug 01 '24	Sale	1085.53	99	107,467	17,783	Aug 05 04:01 PM
Bassler Bonnie L	Director	Aug 02 '24	Proposed Sale	1115.00	756	842,940		Aug 02 10:43 AM
MARION E MCCOURT	Officer	Aug 01 '24	Proposed Sale	1060.86	1,137	1,206,198		Aug 01 04:18 PM
Arthur F. Ryan	Director	Aug 01 '24	Proposed Sale	1079.19	300	323,757		Aug 01 04:02 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Jul 11 '24	Sale	1088.95	1,866	2,031,981	37,937	Jul 12 04:00 PM
McCourt Marion	EVP Commercial	Jul 01 '24	Option Exercise	372.46	1,137	423,487	14,068	Jul 02 04:01 PM
McCourt Marion	EVP Commercial	Jul 01 '24	Sale	1047.11	1,137	1,190,564	12,931	Jul 02 04:01 PM
RYAN ARTHUR F	Director	Jul 01 '24	Sale	1059.24	100	105,924	17,882	Jul 02 04:01 PM
Bassler Bonnie L	Director	Jun 24 '24	Option Exercise	371.40	756	280,778	2,138	Jun 25 04:41 PM
Bassler Bonnie L	Director	Jun 24 '24	Sale	1062.00	756	802,872	1,382	Jun 25 04:41 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Jun 24 '24	Option Exercise	555.67	14,450	8,029,431	50,887	Jun 25 04:39 PM
BROWN MICHAEL S	Director	Jun 14 '24	Option Exercise	625.60	1,535	960,296	2,917	Jun 17 04:01 PM
BROWN MICHAEL S	Director	Jun 14 '24	Sale	1040.00	1,535	1,596,400	1,382	Jun 17 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 12 '24	Sale	1015.94	16,149	16,406,406	0	Jun 13 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 11 '24	Sale	1015.43	9,064	9,203,823	55,134	Jun 13 04:01 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	Jun 06 '24	Sale	1015.02	787	798,821	64,198	Jun 10 04:03 PM
Bassler Bonnie L	Director	Jun 05 '24	Option Exercise	380.95	827	315,046	2,209	Jun 07 04:06 PM
Bassler Bonnie L	Director	Jun 05 '24	Sale	1011.00	827	836,097	1,382	Jun 07 04:06 PM
McCourt Marion	EVP Commercial	Jun 03 '24	Option Exercise	372.46	1,138	423,859	14,069	Jun 05 04:07 PM
McCourt Marion	EVP Commercial	Jun 03 '24	Sale	980.16	1,138	1,115,422	12,931	Jun 05 04:07 PM
RYAN ARTHUR F	Director	Jun 03 '24	Sale	994.50	100	99,450	17,982	Jun 05 04:06 PM
BROWN MICHAEL S	Director	May 28 '24	Option Exercise	625.60	1,172	733,203	2,554	May 29 04:01 PM
BROWN MICHAEL S	Director	May 28 '24	Sale	974.86	1,172	1,142,536	1,382	May 29 04:01 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	May 21 '24	Sale	994.90	1,865	1,855,488	34,678	May 22 04:02 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 17 '24	Sale	979.23	22,830	22,355,714	466,877	May 17 05:57 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	May 16 '24	Sale	972.73	50,000	48,636,545	786,383	May 17 04:06 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	May 15 '24	Sale	975.87	50,000	48,793,727	836,383	May 17 04:04 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 13 '24	Option Exercise	399.66	203,204	81,212,511	577,633	May 15 06:10 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 14 '24	Sale	979.25	25,000	24,481,164	408,200	May 15 06:10 PM
SCHLEIFER LEONARD S	Bd. Co-Chair, President & CEO	May 15 '24	Sale	980.34	10,941	10,725,946	397,259	May 15 06:10 PM
SING GEORGE L	Director	May 03 '24	Option Exercise	413.33	2,000	826,660	28,349	May 06 04:20 PM
McCourt Marion	EVP Commercial	May 01 '24	Sale	889.41	250	222,352	12,931	May 03 04:02 PM
RYAN ARTHUR F	Director	May 01 '24	Sale	899.61	100	89,961	18,082	May 03 04:01 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Jan 02 '24	Sale	900.00	16,848	15,163,200	180,000	May 01 04:00 PM
RYAN ARTHUR F	Director	Apr 01 '24	Sale	962.53	100	96,253	18,182	Apr 03 04:06 PM
McCourt Marion	EVP Commercial	Apr 01 '24	Sale	964.73	250	241,182	13,181	Apr 03 04:05 PM
MURPHY ANDREW J	EVP Research	Mar 13 '24	Option Exercise	399.66	20,000	7,993,200	68,306	Mar 15 04:01 PM
MURPHY ANDREW J	EVP Research	Mar 14 '24	Sale	956.47	5,783	5,531,290	48,306	Mar 15 04:01 PM
RYAN ARTHUR F	Director	Mar 01 '24	Sale	982.05	100	98,205	18,282	Mar 05 04:01 PM
McCourt Marion	EVP Commercial	Mar 01 '24	Sale	967.50	358	346,365	13,431	Mar 05 04:01 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Feb 26 '24	Sale	990.00	1,000	990,000	36,543	Feb 28 04:04 PM
SING GEORGE L	Director	Feb 26 '24	Option Exercise	413.33	1,000	413,330	26,849	Feb 28 04:04 PM
SING GEORGE L	Director	Feb 26 '24	Sale	992.50	1,000	992,500	26,349	Feb 28 04:04 PM
Bassler Bonnie L	Director	Feb 26 '24	Option Exercise	391.92	854	334,700	2,236	Feb 26 04:07 PM
Bassler Bonnie L	Director	Feb 26 '24	Sale	979.25	854	836,280	1,382	Feb 26 04:07 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Feb 22 '24	Sale	967.65	1,000	967,650	37,543	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 22 '24	Option Exercise	413.33	3,000	1,239,990	27,349	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 23 '24	Option Exercise	413.33	500	206,665	26,849	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 22 '24	Sale	965.00	3,000	2,895,000	26,349	Feb 26 04:07 PM
SING GEORGE L	Director	Feb 23 '24	Sale	985.00	500	492,500	26,349	Feb 26 04:07 PM
YANCOPOULOS GEORGE	Bd. Co-Chair, President & CSO	Feb 15 '24	Option Exercise	399.66	172,723	69,030,474	925,209	Feb 20 04:03 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Feb 14 '24	Sale	942.28	10,434	9,831,727	20,378	Feb 16 04:15 PM
Van Plew Daniel P	EVP & General Mgr, Industrial	Feb 09 '24	Option Exercise	378.30	35,375	13,382,510	47,153	Feb 13 04:04 PM
SING GEORGE L	Director	Feb 08 '24	Option Exercise	413.33	500	206,665	26,849	Feb 12 04:02 PM
SING GEORGE L	Director	Feb 09 '24	Option Exercise	413.33	500	206,665	26,849	Feb 12 04:02 PM
SING GEORGE L	Director	Feb 09 '24	Sale	955.00	500	477,500	26,349	Feb 12 04:02 PM
SING GEORGE L	Director	Feb 08 '24	Sale	945.00	500	472,500	26,349	Feb 12 04:02 PM
Fenimore Christopher R.	SVP Finance & CFO	Feb 09 '24	Sale	953.31	4,919	4,689,320	14,372	Feb 12 04:02 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Feb 07 '24	Sale	950.00	1,000	950,000	38,543	Feb 09 04:12 PM
STAHL NEIL	EVP Research and Development	Feb 07 '24	Sale	950.35	8,037	7,637,954	52,019	Feb 08 04:02 PM
STAHL NEIL	EVP Research and Development	Feb 02 '24	Option Exercise	399.66	30,750	12,289,545	82,769	Feb 06 04:08 PM
Landry Robert E	EVP Finance CFO	Feb 02 '24	Option Exercise	378.98	400	151,592	23,974	Feb 06 04:08 PM
McCourt Marion	EVP Commercial	Feb 05 '24	Sale	934.71	1,000	934,710	13,789	Feb 06 04:08 PM
RYAN ARTHUR F	Director	Feb 01 '24	Sale	954.22	100	95,422	18,382	Feb 05 04:05 PM
McCourt Marion	EVP Commercial	Feb 01 '24	Sale	945.61	273	258,152	14,789	Feb 02 04:02 PM
Landry Robert E	EVP Finance CFO	Jan 31 '24	Option Exercise	378.98	400	151,592	23,856	Feb 02 04:02 PM
Bassler Bonnie L	Director	Jan 30 '24	Option Exercise	380.95	827	315,046	2,209	Jan 31 04:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals, Inc

Upgrade your FINVIZ experience